- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05741099
Application and Research of Mesenchymal Stem Cells in Alleviating Severe Development of COVID-19 Infection
February 22, 2023 updated by: Quanhai Li, Hebei Medical University
The Application and Research of Mesenchymal Stem Cells in Alleviating the Severe Development of Novel Coronavirus Infection to Clarify Its Safety and Effectiveness.
This study is to evaluate the safety and efficacy of umbilical cord mesenchymal stem cells Therapy for COVID-19.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Since 2019, novel coronavirus Disease 2019 (COVID-19) has spread and prevailed all over the world.
COVID-19 has a wide range of clinical manifestations of respiratory and non-respiratory symptoms, including mild or severe influenza-like syndrome, respiratory distress or respiratory failure, and may end in multiple organ failure.
Mesenchymal stem cells (MSCS) are considered as ideal seed cells for the treatment of various diseases due to their unique immune regulation, self-renewal and multiple differentiation potentials.
The safety of MSC transplantation in the treatment of COVID-19 patients has been proved by a number of clinical studies, and has shown good clinical efficacy in shortening the course of the disease, alleviating lung damage, and reducing the level of inflammatory factors.
However, previous clinical studies mainly focused on the efficacy of MSC transplantation in critically ill patients of COVID-19, ignoring the important role of cell transplantation in delaying or preventing COVID-19 's progress and preventing reinfection.COVID-19 has spread throughout the country and even the world, and the increase in severe and critical cases has caused a great impact on national medical and health resources.
Stem cell transplantation offers new treatment ideas for COVID-19 patients.
Since the role of cell transplantation in delaying or preventing the progression of light and medium novel coronavirus infection and preventing reinfection has not been clearly reported, this study intends to use MSC transplantation to evaluate the role of stem cells in the occurrence and development of novel coronavirus infection, so as to provide an important reference for the prevention and treatment of COVID-19 by MSC.
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xianyun Wang, Doctor
- Phone Number: 031187156290
- Email: wangxianyun_mbb@126.com
Study Locations
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050030
- Recruiting
- The First Hospital of Hebei Medical University
-
Contact:
- Xianyun Wang, Doctor
- Phone Number: 031187156290
- Email: wangxianyun_mbb@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18-85 years;The diagnosis of COVID-19 infection was clinically classified as Moderate cases, and the criteria were based on Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia(Trial Version 10)
- Having the relevant clinical manifestations of COVID-19 infection.
- Having one or more of the following etiological and serological examination results
- Tested positive for Novel Coronavirus nucleic acid
- Tested positive for Novel Coronavirus antigen
- Novel Coronavirus was isolated and cultured positive
- Novel Coronavirus specific immunoglobulin G reaches a titration of at least 4-fold increase during convalescence compared with the acute phase.
- Moderate cases diagnostic criteria:Persistent high fever > 3 days or (and) cough, Tachypnea etc,but respiratory rate≧30 breaths/ min ,oxygen saturation > 93% on finger pulse oximeter taken at rest. Radiology shows the characteristic manifestations of COVID-19 pneumonia
- There are one or more of the following risk factors for the development of severe / critical severity:
- Patients over 65 years old, especially those who have not been vaccinated against novel coronavirus
- Patients with cardiovascular and cerebrovascular diseases (including hypertension), chronic lung disease, diabetes, chronic liver and kidney disease, tumors and other underlying diseases, as well as maintenance dialysis
- Patients with immune deficiency (such as AIDS, long-term use of corticosteroids or other immunosuppressive drugs resulting in immune dysfunction)
- Patients with Obesity (body mass index ≥30)
- late trimester of pregnancy and perinatal women
- Heavy smoker.
Exclusion Criteria:
- Patients with prior or present tumor history,or precancerous lesions confirmed by pathological examination.
- Patients with active acute myocardial infarction or acute cerebral infarction.
- Pregnant or lactating patients.
- Patients with poorly controlled mental illness.
- Patients addicted to alcohol or drugs.
- Patients Unable or unwilling to sign informed consent or poor compliance.
- Patients with active tuberculosis or influenza virus, adenovirus and other acute respiratory virus infection.
- Patients deemed unsuitable for stem cell therapy by clinicians.
- Patients enrolled in other clinical trials within 3 months.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MSCs group
Patient in Mscs group will receive MSCs implantation by intravenous injection Within 10-15 days of infection
|
Patient in Mscs group will receive MSCs implantation by intravenous injection.
|
Placebo Comparator: comparator
Patients in comparator group will receive placebo treatment Within 10-15 days of infection
|
Patients in comparator group will receive placebo treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effectiveness evaluation
Time Frame: Within 1 year of receiving mesenchymal stem cell transplants
|
The incidence and clinical status of progression to critical type after the third stem cell transplantation were evaluated
|
Within 1 year of receiving mesenchymal stem cell transplants
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hospitalization time
Time Frame: Time period from patient admission to discharge
|
The patient's hospital stay in days should be recorded.
|
Time period from patient admission to discharge
|
oxygenation index(OI)
Time Frame: At the time of our patient's hospitalization and 7 days after receiving the third MSC transplant.
|
The oxygenation index of the patient was quantitatively measured in mmHg.
|
At the time of our patient's hospitalization and 7 days after receiving the third MSC transplant.
|
Oxygen saturation(SaO2)
Time Frame: At the time of our patient's hospitalization and 7 days after receiving the third MSC transplant.
|
The blood oxygen saturation of patients was monitored by oximeter.
|
At the time of our patient's hospitalization and 7 days after receiving the third MSC transplant.
|
Chest CT
Time Frame: At admission, before to the stem cell transplant, and at 1 month, 6 months, and 12 months following the third MSC transplant.
|
A computed tomography (CT) scan of the patient's chest was performed to evaluate the level of inflammation, the scope of the involvement, and the degree of fibrosis in the heart and lungs.
|
At admission, before to the stem cell transplant, and at 1 month, 6 months, and 12 months following the third MSC transplant.
|
Pulmonary function evaluation
Time Frame: At admission, before to the stem cell transplant, and at 1 month, 6 months, and 12 months following the third MSC transplant.
|
Lung ventilation experiments were used to measure the lung volume (in ml) and airway patency (in ml) of patients in order to assess their lung function.
|
At admission, before to the stem cell transplant, and at 1 month, 6 months, and 12 months following the third MSC transplant.
|
Blood biochemical examination
Time Frame: At admission, before to the stem cell transplant, and at 1 month, 6 months, and 12 months following the third MSC transplant.
|
The progression of the lesion was determined by blood chemistry tests on a patient's blood sample, which mostly included liver function: Alanine aminotransferase (U/L),Glutamic oxaloacetic transaminase (U/L), renal function:blood urea nitrogen (mmol/L) and serum creatinine (umol/L), cardiac function: creatine kinase isoenzymes(U/L) and Troponin(ng/ml), and inflammatory factors: C- reactive protein (mg/dl) and Interleukin- 6(Pg/ml) .
|
At admission, before to the stem cell transplant, and at 1 month, 6 months, and 12 months following the third MSC transplant.
|
Echocardiographic examination of heart function
Time Frame: At admission, before to the stem cell transplant, and at 1 month, 6 months, and 12 months following the third MSC transplant.
|
Echocardiography was used to evaluate the patient's myocardial contractility, primarily focusing on left ventricular ejection fraction (LVEF).
|
At admission, before to the stem cell transplant, and at 1 month, 6 months, and 12 months following the third MSC transplant.
|
Safety assessment
Time Frame: Within 1 year of receiving mesenchymal stem cell transplants
|
infusion and allergic reactions, life-threatening adverse events
|
Within 1 year of receiving mesenchymal stem cell transplants
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Xianyun Wang, Doctor, The First Hospital of Hebei Medical University
- Study Chair: Xifeng Jiang, Doctor, The First Hospital of Hebei Medical University
- Study Director: Gang Liu, Master, The First Hospital of Hebei Medical University
- Study Director: Wuzhuang Sun, Master, The First Hospital of Hebei Medical University
- Principal Investigator: Baoyong Yan, Master, The First Hospital of Hebei Medical University
- Principal Investigator: Mingqi Zheng, Master, The First Hospital of Hebei Medical University
- Principal Investigator: Ding Yu, Master, The First Hospital of Hebei Medical University
- Principal Investigator: Le Wang, Master, The First Hospital of Hebei Medical University
- Principal Investigator: Yajie Wang, Master, The First Hospital of Hebei Medical University
- Principal Investigator: Quanhai Li, Master, The First Hospital of Hebei Medical University
- Principal Investigator: Jiawei Yang, Postgraduate, The First Hospital of Hebei Medical University
- Principal Investigator: Tianshuo Li, Postgraduate, The First Hospital of Hebei Medical University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020 Feb 15;395(10223):470-473. doi: 10.1016/S0140-6736(20)30185-9. Epub 2020 Jan 24. No abstract available. Erratum In: Lancet. 2020 Jan 29;:
- Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S, Fan J, Wang W, Deng L, Shi H, Li H, Hu Z, Zhang F, Gao J, Liu H, Li X, Zhao Y, Yin K, He X, Gao Z, Wang Y, Yang B, Jin R, Stambler I, Lim LW, Su H, Moskalev A, Cano A, Chakrabarti S, Min KJ, Ellison-Hughes G, Caruso C, Jin K, Zhao RC. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis. 2020 Mar 9;11(2):216-228. doi: 10.14336/AD.2020.0228. eCollection 2020 Apr.
- Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment. N Engl J Med. 2020 Feb 20;382(8):692-694. doi: 10.1056/NEJMp2000929. Epub 2020 Jan 24. No abstract available.
- Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18. No abstract available. Erratum In: Lancet Respir Med. 2020 Feb 25;:
- Galipeau J, Sensebe L. Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. Cell Stem Cell. 2018 Jun 1;22(6):824-833. doi: 10.1016/j.stem.2018.05.004.
- Hashemian SR, Aliannejad R, Zarrabi M, Soleimani M, Vosough M, Hosseini SE, Hossieni H, Keshel SH, Naderpour Z, Hajizadeh-Saffar E, Shajareh E, Jamaati H, Soufi-Zomorrod M, Khavandgar N, Alemi H, Karimi A, Pak N, Rouzbahani NH, Nouri M, Sorouri M, Kashani L, Madani H, Aghdami N, Vasei M, Baharvand H. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem Cell Res Ther. 2021 Jan 29;12(1):91. doi: 10.1186/s13287-021-02165-4.
- Zanirati G, Provenzi L, Libermann LL, Bizotto SC, Ghilardi IM, Marinowic DR, Shetty AK, Da Costa JC. Stem cell-based therapy for COVID-19 and ARDS: a systematic review. NPJ Regen Med. 2021 Nov 8;6(1):73. doi: 10.1038/s41536-021-00181-9.
- Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol. 2014 Nov;15(11):1009-16. doi: 10.1038/ni.3002.
- Shu L, Niu C, Li R, Huang T, Wang Y, Huang M, Ji N, Zheng Y, Chen X, Shi L, Wu M, Deng K, Wei J, Wang X, Cao Y, Yan J, Feng G. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther. 2020 Aug 18;11(1):361. doi: 10.1186/s13287-020-01875-5.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 28, 2023
Primary Completion (Anticipated)
January 1, 2024
Study Completion (Anticipated)
January 1, 2025
Study Registration Dates
First Submitted
February 10, 2023
First Submitted That Met QC Criteria
February 22, 2023
First Posted (Estimate)
February 23, 2023
Study Record Updates
Last Update Posted (Estimate)
February 23, 2023
Last Update Submitted That Met QC Criteria
February 22, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-MSCs-COVID-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Umbilical cord mesenchymal stem cells implantation
-
Acibadem UniversityUnknownDuchenne Muscular DystrophyTurkey
-
Limin RongCompleted
-
Qingdao UniversityUnknownDilated CardiomyopathyChina
-
Qingdao UniversityUnknownUlcerative Colitis | Mesenchymal Stem Cells | Umbilical CordChina
-
Qingdao UniversityUnknownDiabetes Mellitus | Diabetes Mellitus, Type 1 | Mesenchymal Stem Cells | Umbilical CordChina
-
Central South UniversityUnknown
-
Shenzhen Beike Bio-Technology Co., Ltd.The Second Affiliated Hospital of Kunming Medical UniversityUnknown
-
PT. Prodia Stem Cell IndonesiaRecruiting
-
Institute of Hematology & Blood Diseases HospitalCompletedPeripheral Arterial Disease
-
Translational BiosciencesCompleted